BioCatalystWatch
ARQTWorkspace / ARQT / OverviewCompany library
Arcutis Biotherapeutics, Inc. logo

Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. (ARQT)

Website

Price
Market cap
Next catalystVitiligo Phase 2 topline results and advancement decision: Q4 2026ZORYVE foam (roflumilast foam 0.3%) · Phase 2 dataSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

ZORYVE (roflumilast) cream 0.05%

PDE4

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

ZORYVE (roflumilast) cream 0.05%

PDE4

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

ARQ-234

CD200R

PreINDP1P2P3FilingApproved

Approved / commercial

ZORYVE foam (roflumilast foam 0.3%)

PDE4

Approved

PreINDP1P2P3FilingApproved

PDE4

Approved

PreINDP1P2P3FilingApproved

PDE4

Approved

PreINDP1P2P3FilingApproved
ZORYVE foam (roflumilast foam 0.3%)

PDE4

Approved

PreINDP1P2P3FilingApproved

History / paused

JAK1

PreINDP1P2P3FilingApproved

PDE4

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ARQT PR & News

PR & News

ARQT SEC archive